Language: 简体中文 English



<span style="color:#000000;"><span style="color:#000000;line-height:2;font-family:Microsoft YaHei;font-size:14px;"><span style="line-height:2;font-family:Microsoft YaHei;font-size:14px;">无标题文档</span></span></span>

Long-Hua Chen     Professor

Chief Physician, Professor,
Department of  Radiation Oncology, Nanfang Hospital,
Southern Medical University

The Society for Radiation Oncologists of Guangdong
Medical Doctor Association 
The Union for Radiation Oncologists of Guangdong-
Hongkong-Macao Greater Bay Area (UROG)

Honorary Chair,
Radiation Oncology Society of Guangdong Medical


Brian O’Sullivan


Brian O’Sullivan is a Professor in the Department of Radiation Oncology and the Department of Otolaryngology / Head and Neck Surgery at the University of Toronto, Toronto, Ontario, Canada. He works at the Princess Margaret Hospital (PMH), a Teaching Hospital of the University of Toronto, Toronto, Canada.  He graduated from University College Dublin, Ireland in 1976, and completed a fellowship in medical oncology, a residency and clinical fellowship in radiation oncology, all at PMH.

A past President of the Connective Oncology Society (CTOS) and former Head of both the Sarcoma and H&N Oncology Programs at PMH, is the radiation oncology Chair of the US NCI Head and Neck Steering Committee. He now Leads the Princess Margaret Hospital – University of Hong Kong / Shenzhen Hospital Radiation Oncology Sanming project in China. He has published almost 400 peer-reviewed papers, numerous additional manuscripts, more than 100 invites book chapters and manuscripts, and written or edited 10 oncology textbooks.  He is a member of the TNM Committee of the Union for International Cancer Control (UICC), Chair of the UICC Prognostic Factors Sub-Committee and is UICC head and neck cancer and soft tissue / bone sarcoma liaison to the American Joint Committee on Cancer (AJCC). He is one of three clinicians who are Commissioners of the ICRU.


Anne W. M. LEE

    • Deputy Hospital Chief Executive (Clinical Services), The University of Hong Kong - Shenzhen Hospital
    • Clinical Professor and Head Department of Clinical Oncology, Li Ka Shing Faculty of Medicine
    • Chief of Service, Center of Clinical Oncology, The University of Hong Kong - Shenzhen Hospital
    • Alice Ho Miu Ling Nethersole Charity Foundation Professorship in Holistic Cancer Care

Prof. Anne Lee is currently the Clinical Professor and Head, Department of Clinical Oncology, The University of Hong Kong. In addition, she is Deputy Hospital Chief Executive (Clinical Services) at the University of Hong Kong-Shenzhen Hospital and Chief of Service for the Center of Clinical Oncology at the University of Hong Kong-Shenzhen Hospital in China. She is also the Honorary Consultant and Deputy Chief of Service of Clinical Oncology Departments of Clinical Oncology at Queen Mary Hospital in Hong Kong and Honorary Professor at Peking Union Medical College Hospital.
In addition to her professional qualification as Fellow of the Royal College of Radiologists in Clinical Oncology (United Kingdom) and Fellow of the Hong Kong Academy of Medicine, she was conferred Doctor of Medicine by the University of Hong Kong in 2008, and was awarded the Sir Patrick Manson Gold Medal.
She has been the President of Hong Kong Head and Neck Society and Chairman of Hong Kong Nasopharyngeal Cancer Study Group.  Currently she is the Vice President of Hong Kong College of Radiologists and the Vice Chairman of Hong Kong Anti-Cancer Society.
Prof. Lee's main research contributions focus on nasopharyngeal cancer. She serves in editorial board of many international journals. She also serves in many international academic organizations, including being the Coordinator of the Global Advisory Group and a member of TNM Expert Advisory Panel on Head and Neck Cancers for the Union for International Cancer Control.
Prof. Lee has received many honors.  She was awarded Gilbert H. Fletcher Distinguished Professor Lecturer by The University of Texas, M.D. Anderson Cancer Center, United States, in 2009, Honorary Membership by the European Society for Radiotherapy & Oncology in 2012, Honorary Membership by the Radiological Society of North America in 2013, and Wharton Lecturer by Princess Margaret Cancer Centre, Canada, in 2015.


Feng-Ming (Spring) Kong 
Fellow of American College of Radiology (FACR)
Fellow of American Association for Women Radiologists/Radiation Oncologists (FAAWR)
Fellow of American Society of Radiation Oncology(FASTRO)

Professor of Clinical Oncology Hong Kong University, Hong Kong University SZH
Professor Radiation Oncologist of Case Western Reserve University, University Hospitals Cleveland Medical Center
NIH/NCI R21/P01/R01 funded principal investigator
Co-Chair of NRG Imaging Committee/functional imaging working group
Received numerous awards such as ASCO YIA and ASCO CDA
200+ publications (upto 7000 citations)
Reviewer of over 20+ Journals, served as editorial board member of many top Journals including red Journal, clinical lung cancer, and JCO (IF=26)
Served as expert panelist for NCCN guideline and ACR Practice appropriateness
PI of RTOG1106 on adaptive RT, translational research co-chair of RTOG SBRT trials RTOG618, RTOG813
Served as Chair of Radiation Oncology department and Associate Cancer Center Director at Medical College of Georgia

Served as a co-leader of Thoracic Program at Indiana University School of Medicine and Cancer Center of Georgia (2013-2016)
Chair of National VA field Advisory Board (2010-2013)
President of AAWR  (2015) President of AAWR Research and Foundation (2016)
Founding President of SANTRO (2008-2010) and Chair of SANTRO Board Directors (2010-2012)


Lvhua Wang

Professor of Radiation Oncology
Vice president of National Cancer Center
Vice president of Cancer Hospital, Chinese Academy of Medical Sciences
Vice chairman of Chinese Society of Clinical Oncology (CSCO) Chairman of China Society for Radiation Oncology (CSTRO)



Clinical research on radiation therapy for thoracic cancers, Radiation-induced lung toxicity, translational research on genetics of lung cancer


Promoting IMRT technology of thoracic cancer in China, improving the key techniques for standardized treatment of lung and esophageal carcinoma.

Published Articles:

Over 50 peer-reviews articles, including Journal of clinical oncology, Annals of oncology.


  • Second prize of China Medical Science and technology award
  • First Class Prizes of Ministry of Education Scientific and Technological Progress Award
  • First prize of Chinese Medical Science and Technology


Weixi Shen

M. D., Ph. D of Oncology, Cancer Hospital

Peking Union Medical College

Chinese Academy of Medical Sciences
Director of Department of Medical Oncology

Shenzhen People’s Hospital

President, Shenzhen Anti-cancer Association.
Associate President, Tumor Branch Committee, Shenzhen Doctor Association.
Associate President, Tumor Branch Committee, Guangdong Province Doctor Association.
Council Member, Tumor Branch Committee, World Chinese Medicine Union.
Council Member, China Clinical Cancer Association.
Council Member of Standing Committee, Guangdong Anti-cancer Association.
Council Member of Standing Committee, Guangdong Medical Association.
Executive Council Member, Tumor Branch Committee, China Gerontology Association.
Council Member, Tumor Molecular Target Therapy Committee, China Bio-medicine Engineering Association.
Member of Editing Board, World Journal of Tumor.



Chunxue Bai

Director of Shanghai Respiratory Research Institute

Zhongshan Hospita,Fudan University

Professor Chunxue Bai was trained at Beijing Union Medical College and Shanghai Medical University. He was a Postdoctoral Research Fellow at University of California, San Francisco, from 1997 to 1998. He is the Director of Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University. He serves as Chair of Chinese Alliance against Lung Cancer (CALC), President of Chinese Society of e-Health and Chair of Research Committee for APSR. He was the congress President of APSR 2011.

His major scientific contributions are the understanding of pathogenesis of and therapies for
ARDS, COPD and lung cancer. He has authored more than 500 papers, including 150 papers in SCI indexes and 30 book chapters. He is the honor editor in Chief for International Journal of Respiration. He also serves as the international editorial board member for AJRCCMAJRCMBChest, and associate editor for International Journal of COPD.

He established Chinese Alliance Against Lung Cancer (CALC) in 2012 and launched a campaign of HTH with opening hundred sub-centers, educating thousand specialists for diagnosis and with aim to treat hundred thousand cases of early stage lung cancer from pulmonary nodules each year. He is known for his pioneering work of e-health and his cell phone-based remote monitoring system for lung function and has been included in Who’s Who at ATS. His other achievements including advocacy, teaching, and the exceptional contribution of launching China Day at ATS, ERS, WCLC and APSR with the words "open to the world, become international".


Jing CAI




Fellow of AAPM
Associate Professor (tenured) of Hong Kong Polytechnic Univ.
Adjunct Associate Professor of Duke University
Associate Editor of Medical Physics
Associate Editor of Journal of Applied Clinical Medical Physics
Associate Editor-in-Chief of Cancer Translational Medicine
Editorial Board, Chinese J. of Radio. Med. Prot.
Member of Senate of Hong Kong Polytechnic Univ.
Principle Investigator of >10 grants (NIH, GRF, HMRF, etc.)
Grant reviewer (NIH, DOD, DTF, ORF-RE, etc.)
Reviewer for more than 20 journals
Published > 80 SCI papers, > 200 other publications
Received numerous awards (ACMP YIA, AAPM YIA, etc.)
Director of Education Program Therapy Track, AAPM
Senior Associate Editor of International Journal of Radiation


Laura Dawson 
Department of Radiation Oncology
University of Toronto

Dr Laura Dawson is a radiation oncologist at the Princess Margaret Cancer Centre, and a Professor the Department of Radiation Oncology, University of Toronto. She completed her medical school and radiation oncology residency at the University of Toronto and a fellowship in high precision radiation therapy at the University of Michigan, where she stayed on as a faculty member until 2003, at which time she returned to Canada to develop a hepatobiliary radiation therapy program at the Princess Margaret Cancer Centre. She is an internationally recognized leader in hepatobiliary cancers and liver metastases and in the use of advanced radiation technologies, including stereotactic body radiation therapy (SBRT) and image guided radiation therapy (IGRT). She is the principal investigator of several phase III clinical trials, including RTOG1112, an international randomized trial of SBRT for locally advanced hepatocellular carcinoma and HE.1, a Canadian randomized trial of low dose whole liver radiation therapy to treat painful primary and metastatic liver cancers. She has published over 150 scientific papers. She was a recipient of an ASCO career development award, and her research has been funded by the NIH, CIHR, NCIC CTG, and the Canadian Cancer Society.



Chen Hu

PhD in biostatistics from the University of Michigan, Ann Arbor
Assistant Professor in Johns Hopkins University
Lead Statistician/Voting Member, Lung Cancer Committee, NRG Oncology


Assistant Professor, Johns Hopkins University
Dept. of Oncology, Dept. of Radiation Oncology and Molecular Radiation Sciences, School of Medicine
Biostatistics, Bloomberg School of Public Health
Lead Statistician/Voting Member, Lung Cancer Committee, NRG Oncology
Responsible for all aspects of statistics and data management on all (15+) active NRG lung cancer trials, including associated translational research and patient-reported outcome
NRG Oncology was formed in 2014 and merged by the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG); NRG is one of the four US adult cancer clinical trial cooperative groups under NCI/NCTN (along with Alliance, ECOG-ACRIN, SWOG)
Voting Member, American Society for Radiation Oncology (ASTRO)
Annual Meeting Scientific Program Assembly Committee
Science Council Research Grants Committee
Published more than 100 peer-reviewed articles, reviews, book chapters and abstracts in a variety of journals, e.g., Lancet Oncol, J Clin Oncol, JAMA Oncol, J Thorac Oncol, Int J Radiat Oncol Biol Phys, PNAS, Biostatistics, Statistics in Medicine, etc.
Statistical reviewer for 20+ SCI journals, e.g., Lancet Oncol, J Clin Oncol, JAMA Oncol, IJROBP, Biometrics, Statistics in Medicine, etc.
Statistical expertise and interests include innovative oncology clinical trial design and analysis, prognostic and predictive modeling, machine learning, survival and longitudinal analysis 


Jian-Dong Huang

Endowed Professor, University of Hong Kong


L & T Charitable Foundation Professor in Biomedical Sciences School of Biomedical Sciences, Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR, P.R. China
Deputy Director, Translational Medicine Work Alliance, Grand Bay Area, Guangdong, Hong Kong and Macau
Investigator, HKU-Shenzhen Institue of Research and Innovation
Visiting Professor, the Fourth Military Medical University, Xi’An, China
Visiting Professor, Academy of Military Medical Sciences
Member of the Asia-Pacific International Molecular Biology Organization
Serving as a judge for several international journals, including Nature Methods, Nature Protocols, and reviewers for more than 20 journals
Served as reviewer of The National Natural Science Foundation of China (NSFC) (Major Program) and Guangdong Natural Science Foundation
The first person to conduct synthetic biology research in Hong Kong, one of the leading figures in the field of synthetic biology in China
led the team to publish the first "Science" paper in the field of synthetic biology in China, and many media including Reuters and Science Daily highly praised the results.
Published more than 130 SCI articles, the total number of citations exceeded >3880, and the H-factor was 33
Hosted a number of research projects funded by the Hong Kong Government Research Grants Council, the National Natural Science Foundation, and the 973.

Organized domestic and international academic conferences, including the International Conference on Synthetic Biology (SB4.0, SB5.0). More than 50 invitation reports at home and abroad


Sophie (Shao Hui) Huang

Assistant Professer, M.R.T (T), MSc, MD
Department of Radiation Oncology,
The Princess Margaret Cancer Centre / University of Toronto
Toronto, Ontario, Canada


Brief Description of Responsibilities:
Shao Hui (Sophie) Huang is an Assistant Professor in the Department of Radiation Oncology at the University of Toronto. She was an MD trained in China, and completed her Hons BSc in Radiation Therapy at the University of Toronto / Michener Institute in 2003. Since graduation, she works as a radiation therapist at The Princess Margaret Cancer Centre. Sophie currently divides her time among maintaining the Head-and-Neck Cancer Anthology of Outcomes System at the institution, coordinating the multidisciplinary Head-and-Neck Cancer Conference, clinical and translational research, and delivering radiation treatment for head and neck cancers. She has been the principal investigator, co-investigator and research supervisor in many research projects and has more than 80 peer-reviewed publications and 6 text book chapters, including publications in Lancet Oncology, JCO, and Cancer.  Many of her publications were highly cited and influenced clinical trial design and clinical practice. She was editorial board coordinator for UICC Manual of Clinical Oncology 9th edition, the editor of Annual of Nasopharyngeal Cancer, and the author of several book chapters. She is also reviewer for many scientific journals, including Cancer, EJC, International Journal of Radiation Oncology, Biology, and Physics, Radiotherapy and Oncology, and Head and Neck. Her major interest is to understand clinical behavior and develop prognostic models for head and neck cancer, especially viral related nasopharyngeal and oropharyngeal cancer. She has received many research awards for her research work including Best of ASTRO, research awards in ESTRO and CARO annual scientific meetings.

Educational Preparation: B.Sc (Hons), Radiation Science (Radiation Therapy)
Degree: Hons. B.Sc. (University of Toronto); M.Sc., MD (China)
Major Area of Study: Head & Neck Cancer, Radiation Oncology, and Radiation Therapy
Year Earned: 2003



Paula M. Jacobs 
Associate Director of DCTD

Paula M. Jacobs, PhD, joined NCI after 30 years in the pharmaceutical and medical device industries, where she was a key developer of ultrasmall superparamagnetic iron oxide drugs as magnetic resonance imaging agents and iron replacement therapeutics. She became Deputy Associate Director of DCTD responsible for CIP in 2009, Associate Director in 2011, and Expert Advisor in 2018. Her efforts for NCI have been focused on lowering the scientific, logistical, and regulatory barriers to investigational use of positron emission tomography radiopharmaceuticals for therapeutic drug development by facilitating access to Investigational New Drug (IND) filings and by overseeing research to develop labeled drugs for clinical and preclinical use, particularly for optical imaging agents used to assist surgeons to make complete resections. Another effort is focused on wide-ranging aspects of standardization and quantitative imaging techniques, and a third focus is on genome-imaging correlations. Dr. Jacobs serves on three NCI Experimental Therapeutics (NExT) committees to review and manage the projects chosen for development. She oversees a radiochemistry laboratory and radioactive drug production facility at the Frederick National Laboratory for Cancer Research that provides preclinical and early clinical radiopharmaceuticals in support of therapeutic drug development.

Her industrial experience began at Clinical Assays, a division of Baxter Travenol that manufactured in vitro radioimmunoassays, where she was responsible for process improvements in radioactive tracer synthesis, technical product maintenance, product and process improvements, and manufacturing of all reagents used in the company’s products. At Seragen, a small biotechnology firm, she was General Manager, with profit and loss responsibility for a division that developed, manufactured, and marketed prostaglandin, leukotriene, and small protein immunoassays. Subsequently she joined Advanced Magnetics as Vice President, Development, to help chart a new course for this small biomedical products company. She was responsible for the development of iron oxide magnetic contrast agents from laboratory synthesis through IND submissions, including design of pharmacology, toxicology, and clinical studies. She served as international liaison for technology transfer to licensees, worked with independent physicians in the United States and abroad to develop physician IND trials in magnetic resonance imaging, and collaborated with academic researchers in a variety of preclinical investigations.

Dr. Jacobs has published papers in the areas of organic chemistry, inorganic chemistry, magnetic resonance imaging, positron emission tomography, neuro-oncology, and nephrology.


Jian-Yue (JJ) Jin


Professor, Director of Medical Physics and Dosimetry, Radiation Oncology, Seidman Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH, USA
Associate Editor, Journal of Medical Physics
Founding board member, Sino-American Network of Therapeutic Radiology and Oncology (SANTRO)
NIH R01 Award
ABR board certification in therapeutic medical physics


Allen Li

Tenured professor
Fellow of AAPM

Dr. X. Allen Li is a tenured professor and the Chief of Medical Physics in the Department of Radiation Oncology, Medical College of Wisconsin. He has over 25-years of experience in developing methodologies and technologies to improve radiation therapy for cancer. Areas of his research covers adaptive radiation therapy, MRI-guided radiation therapy, quantitative imaging for radiation response assessment, and radiation outcome modeling for radiation treatment planning. In last five years, his research focus is on MR-guided adaptive radiation therapy. He has been frequently invited, for more than 100 times, to speak nationally and internationally on these topics. Dr. Li's bibliography includes more than 200 peer-reviewed papers, one textbook, 13 book chapters, and nearly 400 conference abstracts. He was the principal investigator for over 30 projects funded by federal or private agencies and co-investigator for 20 funded research projects. Dr. Li has served as a grant peer reviewer for more than 10 funding organizations and as an associate editor or peer reviewer for 18 scientific journals. He is a Fellow of AAPM, and the current president for Sino-American Network for Therapeutic Radiology and Oncology (SANTRO).


Zihai Li

Professor and Founding Director, Institute for Immuno-Oncology, the Ohio State University, Columbus, Ohio

Elected Member of The American Association of Physicians
Member of the American Society of Clinical Investigation (ASCI), American Board of Internal Medicine (ABIM)-certified medical oncologist, and a physician scientist
An expert in the field of GP96/GRP94 chaperone & recently uncovered the roles of platelets
Published130-plus manuscripts
Currently supported by 5 NIH grants (4 R01s and 1 P01).
Earned his medical degrees from Zhengzhou University and Peking Union Medical College, and his Ph.D. in immunology from the Icahn School of Medicine at Mount Sinai.
Completed his internal medicine residency in the Montefiore-Einstein Medical Center and his medical oncology fellowship at the Fred Hutchinson Cancer Research Center.
Served multiple leadership roles in the American Society of Clinical Oncology (ASCO)
Former President and Chair of Board of the Chinese American Hematologist and Oncologist Network (CAHON).
The elected founding Chair of the CSCO Committee of Oversea Experts (2018-2020)


Hui Liu


Professor,  Chief of Thoracic Service, Deputy Chair/Medical Director of Department of Radiation Oncology, Sun Yat-sen University Cancer Center
Member of IASLC staging and prognostic committee
NRG-RTOG full member institute, chief coordinator
Member of ITMIG (thymic tumor) committee


Doug Moseley

Deputy Chief of Medical Physics at the Stronach Regional Cancer Centre at Southlake

Dr. Doug Moseley completed his PhD in the Department of Applied Mathematics at the University of Western Ontario, London, Ontario in 1995.  After 7 years with Honeywell’s Industrial Automation and Control Division in Phoenix AZ, he returned to Canada in 2001.  Doug transitioned to a small bio-medical startup company before landing in the Radiation Therapy Physics department at Princess Margaret Cancer Centre in 2002.  He is an Assistant Professor in the University of Toronto’s Department of Radiation Oncology.  Since 2008, Doug has been the Deputy Chief of Medical Physics at the Stronach Regional Cancer Centre at Southlake.  His current research interests focus on the development of novel image processing techniques as well as the use of image-guidance with cone-beam CT for radiation therapy delivery.  Dr. Moseley received the 2012 U of T Colin R. Woolf Award for Excellence in Continuing Education Teaching.  He is currently certified in Therapeutic Radiologic Physics by the American Board of Radiology.


Juwei Mu

Chief physician
PhD Tutor

Deputy Chief of Thoracic Surgery Department, National Cancer Center, CHCAMS
Chief of Thoracic & General Surgery Department, CHCAMS, Shenzhen Center
Executive Deputy, Shenzhen Quality Control Center of Oncology Treatment
Honorary President of Qinghai Cancer Hospital
Panel of Experts, Standardization of Diagnosis and Treatment of Lung Cancer of National Health and Family Planning Commission
Deputy Director, Thoracic Oncology Chapter of China Health Care International Exchange and Promotion Association
Vice President, Esophageal Cancer Division of Chinese Society of Clinical Oncology (CSCO)
Vice Chairman, Thoracic Surgery Chapter of Chinese Medicine Education Association
Vice President, World Association of Chinese Oncologists (WACO)
Inaugural President, Thoracic Oncology Chapter of WACO
First President, Thoracic Oncologists Chapter of Shenzhen Medical Doctor Associatio


Wai Tong Ng

Honorary clinical associate professor at the University of Hong Kong
Honorary clinical associate professor at the Chinese University of Hong Kong

Dr. Ng received his medical school training at the Chinese University of Hong Kong. Upon completion of his internship training, Dr. Ng joined the Department of Clinical Oncology at Prince of Wales Hospital in 1992 and later Pamela Youde Nethersole Eastern Hospital in 1994.  He attained Fellow of the Royal College of Radiologists in 1997 and was conferred Doctor of Medicine at the University of Hong Kong in 2008. Dr. Ng is currently consultant at the Pamela Youde Nethersole Eastern Hospital, honorary clinical associate professor at the University of Hong Kong, honorary clinical associate professor at the Chinese University of Hong Kong, and past president of the Hong Kong Head and Neck Society. He also serves the editorial board of Oral Oncology and Journal of Hong Kong College of Radiologists, and is also a member of TNM Expert Advisory Panel on Head and Neck Cancers for the UICC. Over the years, Dr. Ng has been actively engaged in clinical research and has contributed to more than 100 publications. His main interest is head and neck oncology.


Daniel A. Pryma 

Associate Professor of Radiology & Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania
Chief of the Division of Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology

Daniel A. Pryma, MD is Associate Professor of Radiology & Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania. He is Chief of the Division of Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology and is co-Leader of the Radiobiology & Imaging Program of the Abramson Cancer Center at the University of Pennsylvania. He is the Past Chair of the American Board of Nuclear Medicine and the President of the Therapy Center of Excellence of the Society of Nuclear Medicine & Molecular Imaging. His research focuses on pre-clinical, translational and clinical testing of therapeutic radiopharmaceuticals, companion diagnostics and image guided therapy. He has led both local and multi-center trials and is the Chair of the Imaging Committee of NRG Oncology. 


Jin-Xiong She

Professor at the University of Florida

Jin-Xiong She, PhD received his college education in China and PhD degree in France.  After a short postdoctoral training, he was quickly promoted to Assistant Professor, Associate Professor, Full and Endowed Professor at the University of Florida (UF).  He served as Division Chief of Experimental Pathology and Director of Research of the UF’s Diabetes Center.  Dr. She was recruited in 2002 to be the Georgia Research Alliance Eminent Scholar in Genomic Medicine at the Medical College of Georgia.  He is also the founding and current Director of the Center for Biotechnology and Genomic Medicine and Professor, Department of Obstetrics and Gynecology as well as the director of two core research facilities for Augusta University and the Georgia Research Alliance: Genomics, and Proteomics & Mass Spectrometry. In his academic career, he has authored over 300-peer reviewed papers with an H-Index of 57 and over 10,000 citations, secured over $100 million in research grants, invited to speak globally.  He mentored 13 doctoral students, 47 post-docs and 12 faculty. Dr. She is one of the top 20 “Georgia Top Medical Researchers” name by the Atlanta Business Chronicle.  He served as President of the Chinese Geneticists in America and President of the American Diabetes Association’s council on Immunology, transplantation and Immunogenetics among other honors.  Dr. She is a serial entrepreneur and has founded or co-founded six companies, the latest of which is Jinfiniti Precision Medicine, Inc. that aims to provide a one-stop shop for precision oncology services focusing on early diagnosis, genetic testing and drug sensitivity testing.


Geng Tian


Winner of Outstanding Young Scientist Award of Science Chinese in 2015
Postdoctoral Cooperative Tutor of Sun Yat-sen University
Master Tutor of Anhui Medical University, Guangzhou Medical University and Shenzhen University
12 SCI Publications as the First Author and/or the Correspondent
Reviewer of over 10+ Journals
PI of 5 CAR-T、TCR-T Clinical Trials of Solid Tumors
Executive Director of Cell Biology Technology Key Laboratory of Translational Medicine of Shenzhen
Standing Committee Member of Oncology Committee of Chinese Research Hospital Association
Vice Chairman of Melanoma Committee of Guangdong Province Anti-Cancer Association
Chairman of Biotherapy Committee of Shenzhen Anti-Cancer Association
Chairman of Shenzhen Cancer Prevention and Early Screening Committee, China Cancer Prevention and Control Alliance













Up To Date 临床顾问







Huanmei Wu

Chair of BioHealth Informatics, School of informatics and Computing,
Indiana University Purdue University Indianapolis (IUPUI)

Chair, Department of BioHealth Informatics
Program Director, Bioinformatics
Program Director, Biomedical Informatics
Center Director, BioHealth Informatics Research Center
Principal investigator, for awards from
NIH/NCI National Cancer Institute
Varian Medical Research
National Institute for Public Safety Health (NIPSH)
Indiana Primary Health Care Association (IPHCA)
The Patient-Centered Outcomes Research Institute (PCORI)
PerkinElmer Inc
Co-Principal investigator
National Science Foundation (NSF)
The Junior Diabetics Research Foundation (JDRF)
Panelist for
Reviewer of various Journals, IEEE/ACM conferences, symposiums and workshops
Co-organizer for the IUPUI Data Science Initiative
Founding member of the Transportation Active Safety Institute (TASI)


Yi-Long Wu

Professor of Oncology,PhD Turtor,

Winner of  Outstanding Science Achievement from IASLC

Director (Tenured) of Guangdong General Hospital
Honorary Director of Guangdong Lung Cancer  Institute
Director of Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer
Chief of the WU JIEPING Oncology Medical Foundation
Former President of Chinese Society of Clinical Oncology (CSCO)
Vice-director of the Precision Medicine of the Chinese Medical Doctor Association
Chairman of Guangdong Association of Clinical Trials (GACT)
President of Chinese Thoracic Oncology Group(CTONG)
Key Member of Board of Directors of the International Association Study of Lung Cancer(IASLC)  and former member of staging committee of the IASLC
Chairman of European Society for Medical Oncology (ESMO) in China



Heng Xie 
M.D., Ph.D., and M.P.H.
Former Officer at National Cancer Institute (NCI)& National Institutes of Health (NIH)

Heng Xie is the Chief Medical Officer at Shenzhen Salubris Pharmaceuticals Co., Ltd. and a senior adviser to the Mayo Clinic Cancer Center, China National Cancer Center, China National Center of Biomedical Analysis, China Health Promotion Foundation and the national editorial committee for Chinese dictionary of oncology. In addition, Dr. Xie is a member of the editorial board of “Cancer Biomarkers”and “Translational Cancer Research”.
Before joining Salubris, Dr. Xie was a senior medical officer/program director in the Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI). Dr. Xie oversaw the research bases of two clinical trials – Southwest Oncology Group (SWOG) and ECOG-ACRIN – and directed investigators’ initiated/NCI supported phase I-III clinical trials. In addition, he was the Chair of the Cancer Prevention and Control Concept Protocol Review Committee for approving new concepts and protocols for cancer trials and a standing member in the Data Safety Monitoring Committee (DSMC) for both SWOG and ECOG-ACRIN.
Before DCP, Dr. Xie worked as a medical officer for the Cancer Therapy and Evaluation Program (CTEP) at the NCI for 9 years and the Supervisory Medical Officer for the Division of Clinical Innovation at the National Center for Advancing Translational Sciences (NCATS) for 5 years. He oversaw surgical oncology and clinical oncology programs that support phase I-III cancer treatment trials at the NCI and managed the Clinical Translational Science Awards (CTSA) program at the NCATS. Dr. Xie not only evaluated numerous protocols for clinical trials, but also published 14 funding initiatives and received many NCI/NIH Merit Awards.


Yaoqin Xi

Professor and PhD Supervisor of Shenzhen Institutes

of Advanced Technology, Chinese Academy of Sciences


Associate Editor of Medical Physics
International Advisory Board Member of Phys Med Biol
Member of National Committee of Clinical Electronics Standard of China
Guangdong Leading Talent of Special Support Plan
Shenzhen High-Caliber Personnel (rank B)
Councilor of Professional Board of Medical Imaging Physics of China
Deputy Director of the Intelligent Orthopaedics Section of the Guangdong Provincial Orthopaedic Association
Committee Member of Society of Molecular Imaging of China
Committee Member of Society of Medical Imaging Physics of China
Committee Member of Journal of Nanoneuroscience
Committee Member of Chinese Journal of Medical Imaging Technology
Member of Chinese Society of Biomedical Engineering (CSBME)
Member of American Association of Physicists in Medicine (AAPM)
Referee of Medical Image Analysis
Referee of IEEE Transactions on Biomedical Engineering
Referee of IEEE Transactions on Information Technology in BioMedicine


Jinming Yu

Professor, Shandong Cancer Hospital

CAE academician, M.D, Ph.D Tutor

Member of Standing Committee of Shandong Province People's Congress
Deputy director of Committee of Education, Science, Culture, Health and Sports of Shandong Province
Honorary Dean of Shandong Academy of Medical Sciences
President of Shandong Cancer Hospital
Senior Experts Contacted by the National Government Health
Deputy President of China Anti-Cancer Association
Honorary President of Chinese Radiation Oncology Committee
Honorary President of Radiotherapy Professional Committee of China Anti-Cancer Association
President of Shandong Anti-Cancer Association
Chief editor and associate editor for multiple magazines, such as
Chinese Journal of Cancer Prevention and Treatment


Shuanghu(Tiger) Yuan


Professor and Chair of Thoracic Radiaiton Oncology Department at Shandong Cancer Hospital & Institute
National leader in science, technology and innovation in the "Ten Thousand People Plan"
Young and middle-aged science and technology innovation leaders in the Ministry of Science and Technology
Winner of Top10 Chinese Young Tumor Scientist Award
State Council Expert for Special Allowance
Chairman of the Executive Committee, CRTOG
Standing Committee of Lung Cancer at CACA and CSCO
Vice Chairman of Youth Committee of CSTRO


Weining Ken Zhen

Fellow of American Society of Radiation Oncology (FASTRO)
Fellow of American College of Radiology (FACR)

Professor and Medical Director of Radiation Oncology
Professor of Otolaryngology-Head and Neck Surgery
The University of Nebraska College of Medicine
Professor of Department of Medical Imaging & Therapeutic Sciences
The University of Nebraska College of Allied Health Professions
Member of ASTRO, ASCO and ACR
Committee member of ASTRO International Education Subcommittee, China group leader
Committee member and board examiner of American Board of Radiology (ABR), Radiation Oncology HNS OLA Examination Committee
Panel member of NCCN Head and Neck Panel
Panel member of NCCN Unknown Primary Panel
Chair of SANTRO Board of Directors
Committee member of International Advisory Board, Committee of Radiation Oncology, Chinese Research Hospital Association (CRHA)
Clinical interests: Head and Neck, Skin, CNS and lung


Lei Zheng

M.D., Ph.D.
Associate professor of Oncology and Surgery in the Gastrointestinal Oncology Program at the Johns Hopkins University School of Medicine

Lei Zheng, M.D., Ph.D. is an associate professor of Oncology and Surgery in the Gastrointestinal Oncology Program at the Johns Hopkins University School of Medicine and lead a large translational program that focuses on the preclinical and clinical development of novel vaccine- and antibody-based rational combination immunotherapy for gastrointestinal cancers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is Director of the Pancreatic Cancer Precision Medicine Program, a Pancreatic Cancer Center of Excellence at Johns Hopkins and Leader of Personalized Medicine Program at the Bloomberg-Kimmel Institute for Cancer Immunotherapy. His clinical work is focused on multidisciplinary management for pancreatic cancer, bile duct cancer, liver metastases, and gastric cancer. In addition, he is a lead researcher in the group of Johns Hopkins Cancer Center’s physician scientists who have developed the pancreatic cancer GVAX vaccine and are currently leading eight investigator-initiated clinical trials of checkpoint inhibitor-based combination immunotherapy.  More recently, his laboratory started to develop neoantigen-based vaccines and nanoparticle based adjuvant systems.  He has also applied his knowledge gained from pancreatic cancer immune-based therapies to the development of a colorectal cancer vaccine and to the development of immunotherapy for bile duct cancer. He is affiliated with the Tumor Immunology Program as a laboratory investigator and possesses a large clinical trial associated biospecimen bank.  His primary laboratory research focus is on the identification of new targets for pancreatic cancer therapies by dissecting tumor microenvironment of pancreatic cancer. Since 2013, he has published over 70 peer-reviewed papers and given more than 30 plenary and keynote speeches in national and international symposia. He is the founding Editor-in-Chief of Annals of Pancreatic Cancer, the only scientific journal that is solely focused on the malignant diseases of the pancreas. He is President of the Chinese American Hematologist and Oncologist Network (CAHON).







大    会    倒    计    时